JUPITER, FL – September 7, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a fully funded proof…
JUPITER, FL – August 9, 2018 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the second quarter and six months ended…
JUPITER, FL – July 26, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Results Highlighted in BioProcess International and the Global Bioprocessing and Bioanalytics Congress 2018
JUPITER, FL – June 18, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…
Three new research collaborations
Positive results in our initial glycoengineering modifications of C1 strains
Achieving high levels of productivity for therapeutic proteins
Board approved a reverse stock split subject to shareholder approval
Recognized industry thought leader joins board
New Chief Accounting Officer appointed
$47.7 million of cash, cash equivalents and investment securities at March 31, 2018
JUPITER, FL -…
JUPITER, FL – April 25, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…
Dyadic International Announces 2017 Year End Results and Recent Developments
$49.1 million of cash, cash equivalents and investment securities as of December 31, 2017
Successfully executed two funded collaborations in 2017 and signed three new collaborations in 2018
Early data generated from our research programs are showing encouraging results for C1 technology
Settlement with the last remaining defendant in…
JUPITER, FL – March 15, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced that Chief Financial Officer Thomas L. Dubinski will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers will assume many of Mr. Dubinski’s duties while remaining in their current positions. Ping W. Rawson, the Company’s…
JUPITER, FL – March 13, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the year…
JUPITER, FL – February 27, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…
